pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,781 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1185Endpoints903BioPharma Dive348BioSpace317Fierce Biotech302onclive165raps107globenewswire health
therapy area
allOncology7784Rare Disease1891Cardiology1781Immunology1514Hematology1329Vaccines1207Pulmonology
  • Experts caution limited knowledge of hantavirus after outbreak on African offshore cruise ship
    Health officials are monitoring a hantavirus outbreak on the MV Hondius, a cruise ship that was moored off the western coast of Africa. The situation has drawn attention because passengers were con…
    STAT · 4mo agoNeutral↗ source
  • FDA approves nivolumab plus AVD for untreated advanced-stage Hodgkin lymphoma
    Dr. Alex Herrera, a professor and chief of lymphoma at City of Hope, highlighted the recent FDA clearance of the combination of nivolumab with the chemotherapy regimen AVD for patients with newly d…
    onclive · 4mo agoApprovalPositive↗ source
← prev
page 99 of 112
next →
73
fda recalls70
fda medwatch60
fda press38
1203
Psychiatry & CNS870
Ophthalmology505
Pain483
Endocrinology & Metabolism483
Infectious Disease450
  • Novo Nordisk lifts 2026 guidance as Wegovy sales surge in Q1
    Novo Nordisk reported its first‑quarter results, noting that sales and operating profit are expected to decline less than previously forecast. The company said adjusted sales fell between 4% and 1…
    BioPharma Dive · 4mo agoEarningsPositive↗ source
  • GSK signs $1 billion siRNA partnership with China's SiranBio to target obesity
    GSK is expanding its cardiometabolic portfolio by entering a new collaboration with Chinese biotech SiranBio. The agreement is valued at $1 billion in biobucks and focuses on developing siRNA ther…
    Endpoints · 4mo agoDealPositive↗ source
  • Novo Nordisk shares rise as Wegovy updates improve earnings outlook
    Novo Nordisk reported that recent data on its obesity drug Wegovy were less negative than expected, helping the company’s earnings. The improved outlook lifted Novo Nordisk’s share price, narrowin…
    STAT · 4mo agoEarningsPositive↗ source
  • Neoadjuvant T-DXd then THP cuts residual cancer burden vs standard chemo in high-risk HER2-positive breast cancer
    The DESTINY‑Breast11 trial compared three neoadjuvant approaches for patients with high‑risk HER2‑positive early‑stage breast cancer: T‑DxD followed by paclitaxel, trastuzumab and pertuzumab (THP),…
    onclive · 4mo agoPositive readoutPositive↗ source
  • Eli Lilly to invest $4.5 billion in new manufacturing facilities across Indiana
    Eli Lilly announced a $4.5 billion allocation for new manufacturing projects in Indiana. The company said the funds will be used to build and upgrade production sites across the state, expanding it…
    Endpoints · 4mo agoPositive↗ source
  • Avalo Therapeutics reports Phase 2 success in inflammatory skin disorder and secures $375M financing
    Avalo Therapeutics announced on May 6, 2026 that its experimental immunology drug met its primary endpoints in a Phase 2 study of an inflammatory skin condition. The trial tested two dose levels,…
    Endpoints · 4mo agoPositive readoutPositive↗ source
  • Avalo's Phase 2 data lifts shares 45% as skin drug shows 42% response in hidradenitis suppurativa
    Avalo Therapeutics reported that its experimental therapy abdakibart met the primary goal of a Phase 2 trial in patients with hidradenitis suppurativa. Both low and high dose groups achieved respon…
    BioPharma Dive · 4mo agoPositive readoutPositive↗ source
  • New SGO 2026 data show frontline checkpoint inhibitors give 4-year survival boost and almost no relapses after two years in dMMR cancers
    Data presented at the 2026 Society of Gynecologic Oncology meeting highlight the performance of frontline checkpoint inhibitor regimens in patients with deficient mismatch repair (dMMR) cancers. T…
    onclive · 4mo agoPositive readoutPositive↗ source
  • White House drug strategy endorses treatment but tightens funding for fentanyl test strips
    The White House released a new drug‑policy document on May 4 that lists public‑health measures such as wider access to the overdose‑reversal drug naloxone, medication‑assisted treatment, and the di…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Experts favor quadruplet regimens for newly diagnosed multiple myeloma, but transplant role remains debated
    At a recent multiple myeloma meeting, Dr. Ajai Chari of UCSF reviewed current frontline treatment strategies for newly diagnosed patients. He said that data from several phase-3 trials have shifte…
    onclive · 4mo agoNeutral↗ source
  • Lonza plans new ADC manufacturing site and workforce boost to capture commercial market
    Lonza said it aims to become a leading supplier of antibody-drug conjugates (ADCs) for commercial use. The Swiss contract manufacturing organization highlighted the growing demand for ADCs and its…
    Endpoints · 4mo agoPositive↗ source
  • FDA accepts supplemental NDA for taletrectinib targeting ROS1‑positive lung cancer
    The U.S. Food and Drug Administration has accepted a supplemental New Drug Application for taletrectinib, a targeted therapy aimed at patients with ROS1‑positive non‑small cell lung cancer. The fi…
    onclive · 4mo agoRegulatoryNeutral↗ source
  • Administration releases detailed report on most-favored-nation drug pricing, projects $529 billion savings
    The White House Council of Economic Advisers released its most detailed analysis yet of the administration's most-favored-nation drug pricing policy. The report defines the MFN pricing approach, w…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Experts highlight lack of reliable biomarkers for melanoma immunotherapy response
    Dr. Mario Sznol, a professor of clinical medical oncology at the University of Miami, discussed the ongoing difficulty of predicting which patients with metastatic melanoma will benefit from immune…
    onclive · 4mo agoNegative↗ source
  • Utah invests in AI supercomputer to boost health research and biotech innovation
    State of Utah announced a major investment in artificial intelligence and high-performance computing infrastructure aimed at accelerating health research. The new AI supercomputer, managed by the…
    onclive · 4mo agoPositive↗ source
  • Expert Consensus Offers Guidance on Evolving Multiple Myeloma Treatment Strategies
    A 2025 expert consensus presented at the Bridging the Gaps meeting highlighted how quickly multiple myeloma care is changing and gave clinicians practical advice for navigating expanding treatment…
    onclive · 4mo agoNeutral↗ source
  • Amgen and AbbVie report Inflation Reduction Act negotiations dent Q1 sales
    Amgen and AbbVie disclosed in their first-quarter earnings that the Inflation Reduction Act is already affecting their sales. The companies said the first set of drug-price negotiations required b…
    Endpoints · 4mo agoEarningsNegative↗ source
  • Sanofi requests removal of teplizumab from FDA fast-track voucher program after director dispute
    Sanofi has formally asked the Food and Drug Administration to withdraw its type 1 diabetes therapy, teplizumab, from the new speedy review voucher program overseen by Commissioner Marty Makary. Th…
    STAT · 4mo agoRegulatoryNegative↗ source
  • Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline
    Centered around a glaucoma therapy in mid-stage testing, the deal is Bayer’s first drug company acquisition in several years and potentially its largest since it purchased AskBio in 2020.
    BioPharma Dive · 4mo agoDealNeutral↗ source
  • Color Health expands into cancer treatment coordination with virtual tumor boards
    Color Health, a telehealth firm that currently coordinates cancer screening, is moving into providing and coordinating actual cancer care services. CEO Othman Laraki says the growing complexity of…
    STAT · 4mo agoPositive↗ source
  • FDA authorizes fruit-flavored vapes amid political pressure, sparking debate over youth risk and quitting aid
    The U.S. Food and Drug Administration granted its first authorization for fruit-flavored e-cigarettes on Tuesday, adding mango- and blueberry-tasting products from Los Angeles-based Glas to its app…
    STAT · 4mo agoRegulatoryNeutral↗ source
  • Madrigal's Rezdiffra sales top forecasts as Gilead announces job cuts
    Madrigal Pharmaceuticals reported first‑quarter sales of its MASH drug Rezdiffra at $311 million, roughly $10 million above analyst expectations, according to TD Cowen. The outperformance highligh…
    Endpoints · 4mo agoEarningsNeutral↗ source
  • Former Orbital scientists launch ParcelBio with $13 million seed round to boost mRNA therapy durability
    Two former Orbital Therapeutics scientists, Chris Carlson and David Weinberg, have founded a new company called ParcelBio. The startup aims to address a technical limitation that has hindered the…
    Endpoints · 4mo agoDealPositive↗ source